Skip to main content
Erschienen in: Brain Tumor Pathology 2/2020

02.05.2020 | Original Article

Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort

verfasst von: Junya Fukai, Hideyuki Arita, Toru Umehara, Ema Yoshioka, Tomoko Shofuda, Daisuke Kanematsu, Yoshinori Kodama, Masayuki Mano, Manabu Kinoshita, Yoshiko Okita, Masahiro Nonaka, Takehiro Uda, Naohiro Tsuyuguchi, Daisuke Sakamoto, Yuji Uematsu, Naoyuki Nakao, Kanji Mori, Yonehiro Kanemura

Erschienen in: Brain Tumor Pathology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Aging is a known negative prognostic factor in glioblastomas (GBM). Whether particular genetic backgrounds are a factor in poor outcomes of elderly patients with GBM warrants investigation. We aim to elucidate any differences between older and younger adult patients with IDH-wildtype GBM regarding both molecular characteristics and clinical outcomes. We collected adult cases diagnosed with IDH-wildtype GBM from the Kansai Network. Clinical and pathological characteristics were analyzed retrospectively and compared between older (≥ 70 years) and younger (≤ 50 years) cases. Included were 92 older vs. 33 younger cases. The older group included more patients with preoperative Karnofsky performance status score < 70 and had a shorter survival time than the younger group. MGMT promoter was methylated more frequently in the older group. TERT promoter mutation was more common in the older group. There were significant differences in DNA copy-number alteration profiles between age groups in PTEN deletion and CDK4 amplification/gain. In the older group, no molecular markers were identified, but surgical resection was an independent prognostic factor. Age-specific survival difference was significant in the MGMT methylated and TERT wildtype subgroup. Elderly patients have several potential factors in poor prognosis of glioblastomas. Varying molecular profiles may explain differing rates of survival between generations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Louis DN, von Deimling A, Cavenee WK (2016) Diffuse astrocytic and oligodendroglial tumours. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, revised, 4th edn. IARC, Lyon, pp 16–77 Louis DN, von Deimling A, Cavenee WK (2016) Diffuse astrocytic and oligodendroglial tumours. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, revised, 4th edn. IARC, Lyon, pp 16–77
2.
Zurück zum Zitat Committee of Brain Tumor Registry of Japan (2017) Report of Brain Tumor Registry of Japan (2005–2008), Vol. 14. Neurol Med Chir (Tokyo) 57(suppl.):1–102 Committee of Brain Tumor Registry of Japan (2017) Report of Brain Tumor Registry of Japan (2005–2008), Vol. 14. Neurol Med Chir (Tokyo) 57(suppl.):1–102
3.
Zurück zum Zitat Sasaki T, Fukai J, Kodama Y et al (2018) Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors. J Neurooncol 140:329–339CrossRef Sasaki T, Fukai J, Kodama Y et al (2018) Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors. J Neurooncol 140:329–339CrossRef
4.
Zurück zum Zitat Bozdag S, Li A, Riddick G et al (2013) Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PLoS ONE 8:e62982CrossRef Bozdag S, Li A, Riddick G et al (2013) Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PLoS ONE 8:e62982CrossRef
5.
Zurück zum Zitat Ostrom QT, Kinnersley B, Armstrong G et al (2018) Age-specific genome-wide association study in glioblastoma identifies increasedproportion of 'lower grade glioma'-like features associated with younger age. Int J Cancer 143:2359–2366CrossRef Ostrom QT, Kinnersley B, Armstrong G et al (2018) Age-specific genome-wide association study in glioblastoma identifies increasedproportion of 'lower grade glioma'-like features associated with younger age. Int J Cancer 143:2359–2366CrossRef
6.
Zurück zum Zitat The Cancer Genome Atlas Research Network (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:1498–2481CrossRef The Cancer Genome Atlas Research Network (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:1498–2481CrossRef
7.
Zurück zum Zitat Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508CrossRef Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508CrossRef
8.
Zurück zum Zitat Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468CrossRef Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468CrossRef
9.
Zurück zum Zitat Arita H, Yamasaki K, Matsushita Y et al (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4:79CrossRef Arita H, Yamasaki K, Matsushita Y et al (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4:79CrossRef
10.
Zurück zum Zitat Weller M, Weber RG, Willscher E et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693CrossRef Weller M, Weber RG, Willscher E et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693CrossRef
11.
Zurück zum Zitat Umehara T, Arita H, Yoshioka E et al (2019) Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. Acta Neuropathol Commun 7:99CrossRef Umehara T, Arita H, Yoshioka E et al (2019) Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. Acta Neuropathol Commun 7:99CrossRef
12.
Zurück zum Zitat Wick W, Weller M, van den Bent M et al (2014) MGMT testing–the challenges for biomarker-based glioma treatment. Nat Rev Neurol 10:372–385CrossRef Wick W, Weller M, van den Bent M et al (2014) MGMT testing–the challenges for biomarker-based glioma treatment. Nat Rev Neurol 10:372–385CrossRef
13.
Zurück zum Zitat Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926CrossRef Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926CrossRef
14.
Zurück zum Zitat Kinoshita M, Sakai M, Arita H et al (2016) Introduction of high throughput magnetic resonance T2-weighted image texture analysis for WHO grade 2 and 3 gliomas. PLoS ONE 11:e0164268CrossRef Kinoshita M, Sakai M, Arita H et al (2016) Introduction of high throughput magnetic resonance T2-weighted image texture analysis for WHO grade 2 and 3 gliomas. PLoS ONE 11:e0164268CrossRef
15.
Zurück zum Zitat Okita Y, Nonaka M, Shofuda T et al (2014) (11)C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas. Clin Neurol Neurosurg 125:212–216CrossRef Okita Y, Nonaka M, Shofuda T et al (2014) (11)C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas. Clin Neurol Neurosurg 125:212–216CrossRef
16.
Zurück zum Zitat Jeuken J, Cornelissen S, Boots-Sprenger S et al (2006) Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 8:433–443CrossRef Jeuken J, Cornelissen S, Boots-Sprenger S et al (2006) Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 8:433–443CrossRef
17.
Zurück zum Zitat Jeuken J, Sijben A, Alenda C et al (2009) Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 19:661–671CrossRef Jeuken J, Sijben A, Alenda C et al (2009) Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 19:661–671CrossRef
18.
Zurück zum Zitat Álvarez de Eulate-Beramendi S, Álvarez-Vega MA, Balbin M et al (2016) Prognostic factors and survival study in high-grade glioma in the elderly. Br J Neurosurg 30:330–336CrossRef Álvarez de Eulate-Beramendi S, Álvarez-Vega MA, Balbin M et al (2016) Prognostic factors and survival study in high-grade glioma in the elderly. Br J Neurosurg 30:330–336CrossRef
19.
Zurück zum Zitat Fukai J (2018) Clinical and pathological aspects of diffuse gliomas in the elderly. Prog Neuro Oncol 25:1–12 Fukai J (2018) Clinical and pathological aspects of diffuse gliomas in the elderly. Prog Neuro Oncol 25:1–12
20.
Zurück zum Zitat Cimino PJ, McFerrin L, Wirsching HG et al (2018) Copy number profiling across glioblastoma populations has implications for clinical trial design. Neuro Oncol 20:1368–1373CrossRef Cimino PJ, McFerrin L, Wirsching HG et al (2018) Copy number profiling across glioblastoma populations has implications for clinical trial design. Neuro Oncol 20:1368–1373CrossRef
21.
Zurück zum Zitat Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Cancer genome atlas research network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–522CrossRef Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Cancer genome atlas research network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–522CrossRef
22.
Zurück zum Zitat Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437CrossRef Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437CrossRef
23.
Zurück zum Zitat Lee Y, Scheck AC, Cloughesy TF et al (2008) Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 1:52CrossRef Lee Y, Scheck AC, Cloughesy TF et al (2008) Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 1:52CrossRef
Metadaten
Titel
Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort
verfasst von
Junya Fukai
Hideyuki Arita
Toru Umehara
Ema Yoshioka
Tomoko Shofuda
Daisuke Kanematsu
Yoshinori Kodama
Masayuki Mano
Manabu Kinoshita
Yoshiko Okita
Masahiro Nonaka
Takehiro Uda
Naohiro Tsuyuguchi
Daisuke Sakamoto
Yuji Uematsu
Naoyuki Nakao
Kanji Mori
Yonehiro Kanemura
Publikationsdatum
02.05.2020
Verlag
Springer Singapore
Erschienen in
Brain Tumor Pathology / Ausgabe 2/2020
Print ISSN: 1433-7398
Elektronische ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-020-00363-1

Weitere Artikel der Ausgabe 2/2020

Brain Tumor Pathology 2/2020 Zur Ausgabe

Preface

Preface

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.